Alrich Gray, MD
Cardiovascular Disease · Great Falls, MTNPI 1952372294
Payments from drug & device makers
Across 463 payments — averaging $73.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$12K
- Medical Device Business Services, Inc.$6K
- Abbott$5K
- Boston Scientific$4K
- Atricure, Inc.$2K
- Biosense Webster, Inc.$1K
- plus $4K from 20 others
What the payments were for
- Travel & lodging$21,28063%
- Food & beverage$12,41237%
- Education$1490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 116 | $12,479 |
| Medical Device Business Services, Inc. | 31 | $5,757 |
| Abbott | 31 | $4,780 |
| Boston Scientific | 39 | $3,964 |
| Atricure, Inc. | 11 | $1,868 |
| Biosense Webster, Inc. | 41 | $1,447 |
| E.r. Squibb & Sons, L.L.C. | 27 | $505 |
| Novartis | 31 | $468 |
| AstraZeneca | 18 | $435 |
| Johnson & Johnson | 31 | $399 |
| Amgen | 20 | $319 |
| Pfizer | 16 | $310 |
| Merck | 13 | $252 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $161 |
| Cook Medical LLC | 6 | $146 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $109 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $87 |
| Impulse Dynamics (USA) Inc. | 1 | $85 |
| Abiomed | 2 | $73 |
| Preventice Services, LLC | 2 | $51 |
| Cardiovascular Systems Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Chiesi USA, Inc. | 1 | $25 |
| Philips North America LLC | 1 | $18 |
| Terumo Medical Corporation | 1 | $18 |
| Cordis US CORP. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$5,142
- OPTIS$2,618
- GENERAL - THERAPIES$2,093
- ARCTIC FRONT ADVANCE$1,768
- HawkOne$1,553
- Micra$1,412
- Xience V coronary stent system$1,311
- Arctic Front$1,275
- RHYTHMIA$868
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, MODELS$672
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$650
- PulseSelect$620
- CARDIOBLATE CRYOFLEX$443
- NA$279
- SYNERGY ABLATION SYSTEM$250
- Diamondback Coronary$151
- CryoConsole$138
- ARCALYST$135
- MitraClip$124
- AFFERA MAPPING SYSTEM$100
How this compares
$33,841 in reported general payments places this provider in the 85th percentile of 49 cardiovascular disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 513 | $618,401 |
| EntrestoSacubitril/Valsartan | 198 | $295,844 |
| XareltoRivaroxaban | 193 | $207,496 |
| FarxigaDapagliflozin Propanediol | 124 | $136,406 |
| BrilintaTicagrelor | 97 | $77,676 |
| MultaqDronedarone Hcl | 26 | $33,701 |
| Repatha SureclickEvolocumab | 34 | $25,245 |
| JardianceEmpagliflozin | 16 | $23,885 |
| Dofetilide | 54 | $11,991 |
| Metoprolol Succinate | 677 | $10,565 |
| Praluent PenAlirocumab | 18 | $8,481 |
| Repatha SyringeEvolocumab | 12 | $7,538 |
| Flecainide Acetate | 171 | $5,870 |
| Atorvastatin Calcium | 371 | $3,642 |
| Amlodipine Besylate | 440 | $2,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $310 | $618,401513 claims |
| NovartisEntresto | $468 | $295,844198 claims |
| AstraZenecaFarxiga, Brilinta | $435 | $214,082221 claims |
| Johnson & JohnsonXarelto | $399 | $207,496193 claims |
| Sanofi-aventis U.S. LLCMultaq | $28 | $33,70126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 49 cardiovascular disease providers in Montana.
Other cardiovascular disease in Great Falls
- Jorge CastrizGreat Falls$73K
- Michael RitchieGreat Falls$5K
- Miroslaw SochanskiGreat Falls$1K
- Eve GillespieKalispell$1.4M
- Michael ReedMissoula$637K
- Benjamin PlankBillings$191K
- Gregory WoodMissoula$68K
- Robert MitchellKalispell$23K
- Jocelyn SpoonMissoula$17K
- Preston SchneiderBozeman$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.